StockData
McKesson Corp logo

McKesson Corp (MCK) KPIs and segments

MCKNYSEWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends March 31
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 16/3027% above fair value
$1084.43−7.24 (-0.66%)

Close on Nov 18, 2026Market cap $126.43BP/E 29.0Yield 0.29%

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của McKesson · năm tài chính kết thúc ngày 31 tháng 3

Nhìn nhanh KPI của McKesson: 36 chỉ số vận hành, trong đó có GLP-1 Medications Distribution Revenue, U.S. Pharmaceutical Primary Distribution Centers và Health Mart Independent Pharmacies in U.S. Franchise, lấy từ 139 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Năm tài chính của McKesson kết thúc ngày 31 tháng 3 — Q1 FY27 = CQ2 2026 (quý dương lịch).

Periods

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q1 FY27
Q4 FY26
Q3 FY26
Q2 FY26
Q1 FY26
Q4 FY25
Q3 FY25
Q2 FY25
Q1 FY25
Q4 FY24
Q3 FY24
Q2 FY24
U.S. Pharmaceutical($M)
89,95483,16687,11085,72671,71568,79073,02369,766
North American Pharmaceutical($M)
86,77379,12088,32286,48182,72976,94381,19880,018
Oncology & Multispecialty($M)
14,22212,71113,01012,04410,6589,4319,4939,157
International($M)
3,7383,4613,8603,7093,6913,5483,6393,475
Medical-Surgical Solutions($M)
2,8192,8682,9912,9472,7012,8532,9492,9462,6362,8333,0312,834
Prescription Technology Solutions($M)
1,5661,4951,5001,3761,4341,3391,3711,2651,2411,1801,2051,140
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)1
Prescription Technology Solutions($M)
0-2-10-1-1-3-3-4
International($M)
-13-25
Oncology & Multispecialty($M)
-18-14-17-23-24-24-27-19
Medical-Surgical Solutions($M)
-27-13-24-32-25-34-36-42-51
North American Pharmaceutical($M)
-64-115-84-74-61-85-62-66
U.S. Pharmaceutical($M)
-73-28
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)4
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)4
GLP-1 Medications Distribution Revenue ($M)($M)2
15,00014,00014,00013,20012,10010,90010,90010,4008,8007,500
GLP-1 Distribution Revenue YoY Growth (%)(%)
24.0%22.0%26.0%24.0%38.0%46.0%45.0%47.0%26.0%24.0%
GLP-1 Distribution Revenue YoY Dollar Increase ($M)($M)
3,0002,0003,0002,6003,3003,5003,4003,3001,8001,500
GLP-1 Distribution Revenue Sequential QoQ Growth (Disclosed in Selected Quarters Only; Missing Q2 FY26)(%)
13.0%-4.0%7.0%6.0%11.0%17.0%
North American Pharmaceutical — Segment Revenue ($M)($M)8
86,77379,12088,32286,48182,72976,94381,19880,01866,348
North American Pharmaceutical — GAAP Operating Profit/(Loss) ($M)($M)
9031,1571,0558525941,152744347702
North American Pharmaceutical — Non-GAAP Adjusted Operating Profit ($M)($M)
894980872851749885822754684
North American Pharmaceutical — Pre-Tax Non-GAAP Adjustments to Operating Profit ($M)($M)
-9-177-183-1155-26778407-18
North American Pharmaceutical — GAAP Operating Profit Margin (%)(%)
1.0%1.5%1.2%1.0%0.7%1.5%0.9%0.4%1.1%
North American Pharmaceutical — Non-GAAP Adjusted Operating Profit Margin (%)(%)
1.0%1.2%1.0%1.0%0.9%1.2%1.0%0.9%1.0%
North American Pharmaceutical — Other Segment Expense, Net (ASU 2023-07 Significant Expense, $M)($M)
85,87077,96387,26785,62982,13575,79180,45479,67165,646
North American Pharmaceutical — Segment Depreciation & Amortization ($M)($M)
393634323231334348
North American Pharmaceutical — Segment Expenditures for Long-Lived Assets ($M)($M)
6411584746185626630
Oncology & Multispecialty — Segment Revenue ($M)($M)8
14,22212,71113,01012,04410,6589,4319,4939,1578,781
Oncology & Multispecialty — GAAP Operating Profit/(Loss) ($M)($M)
325301304332212217202200148
Oncology & Multispecialty — Non-GAAP Adjusted Operating Profit ($M)($M)
405385366397287252233232219
Oncology & Multispecialty — Pre-Tax Non-GAAP Adjustments to Operating Profit ($M)($M)
808462657535313271
Oncology & Multispecialty — GAAP Operating Profit Margin (%)(%)
2.3%2.4%2.3%2.8%2.0%2.3%2.1%2.2%1.7%
Oncology & Multispecialty — Non-GAAP Adjusted Operating Profit Margin (%)(%)
2.9%3.0%2.8%3.3%2.7%2.7%2.5%2.5%2.5%
Oncology & Multispecialty — Other Segment Expense, Net (ASU 2023-07 Significant Expense, $M)($M)
13,89712,41012,70611,71210,4469,2149,2918,9578,633
Oncology & Multispecialty — Segment Depreciation & Amortization ($M)($M)
666463714236373738
Oncology & Multispecialty — Segment Expenditures for Long-Lived Assets ($M)($M)
181417232424271918
Prescription Technology Solutions (RxTS) — Segment Revenue ($M)($M)7
1,5661,4951,5001,3761,4341,3391,3711,2651,2411,1801,2051,140
Prescription Technology Solutions (RxTS) — Non-GAAP Adjusted Operating Profit ($M)($M)
303322277261269285235218223212193209
Prescription Technology Solutions (RxTS) — Pre-Tax Non-GAAP Adjustments to Operating Profit ($M)($M)
7736161716371613202415-29
Prescription Technology Solutions (RxTS) — GAAP Operating Profit Margin (%)(%)
14.4%19.1%17.4%17.7%17.6%18.5%16.0%16.2%16.4%15.9%14.8%20.9%
Prescription Technology Solutions (RxTS) — Non-GAAP Adjusted Operating Profit Margin (%)(%)
19.4%21.5%18.5%19.0%18.8%21.3%17.1%17.2%18.0%18.0%16.0%18.3%
Prescription Technology Solutions (RxTS) — Other Segment Expense, Net (ASU 2023-07 Significant Expense, $M)($M)
1,3401,2091,2391,1321,1811,0911,1521,0601,038
Prescription Technology Solutions (RxTS) — Segment Depreciation & Amortization ($M)($M)
192021202121222221
Prescription Technology Solutions (RxTS) — Segment Expenditures for Long-Lived Assets ($M)($M)
021011334
Medical-Surgical Solutions — Segment Revenue ($M)($M)7
2,8192,8682,9912,9472,7012,8532,9492,9462,6322,8373,0312,834
Medical-Surgical Solutions — Non-GAAP Adjusted Operating Profit ($M)($M)
195271265249244285294243200248282254
Medical-Surgical Solutions — Pre-Tax Non-GAAP Adjustments to Operating Profit ($M)($M)
73390292358251528351410
Medical-Surgical Solutions — GAAP Operating Profit Margin (%)(%)
4.3%8.1%8.9%7.5%8.2%8.0%9.1%3.1%7.3%7.5%8.8%8.6%
Medical-Surgical Solutions — Non-GAAP Adjusted Operating Profit Margin (%)(%)
6.9%9.5%8.9%8.5%9.0%10.0%10.0%8.3%7.6%8.7%9.3%9.0%
Medical-Surgical Solutions — Other Segment Expense, Net (ASU 2023-07 Significant Expense, $M)($M)
2,6972,6362,7262,7272,4802,6262,6802,8552,448
Medical-Surgical Solutions — Segment Depreciation & Amortization ($M)($M)
262526232224232223
Medical-Surgical Solutions — Segment Expenditures for Long-Lived Assets ($M)($M)
271324322534364251
Other (Remaining International / Norwegian Operations) — Segment Revenue ($M)($M)8
0101335302305257283265281
Other (Remaining International / Norwegian Operations) — GAAP Operating Profit/(Loss) ($M)($M)
051831281310141317
Other (Remaining International / Norwegian Operations) — Non-GAAP Adjusted Operating Profit ($M)($M)
082825139111414
Other (Remaining International / Norwegian Operations) — Pre-Tax Non-GAAP Adjustments to Operating Profit ($M)($M)
0-510-3-30-1-31-3
Other (Remaining International / Norwegian Operations) — GAAP Operating Profit Margin (%)(%)
0.0%512.9%9.3%9.3%4.3%3.9%5.0%4.9%6.1%
Other (Remaining International / Norwegian Operations) — Non-GAAP Adjusted Operating Profit Margin (%)(%)
0.0%7.9%8.4%8.3%4.3%3.5%3.9%5.3%5.0%
Other (Remaining International / Norwegian Operations) — Other Segment Expense, Net (ASU 2023-07 Significant Expense, $M)($M)
0-417304274292247269252264
Other (Remaining International / Norwegian Operations) — Segment Depreciation & Amortization ($M)($M)
000134455
Other (Remaining International / Norwegian Operations) — Segment Expenditures for Long-Lived Assets ($M)($M)
014415345
Total Reportable Segments & Other — GAAP Operating Profit ($M)($M)5
1,5762,4941,9161,6761,2931,8541,4488561,2621,5308791,141
Total Reportable Segments & Other — Non-GAAP Adjusted Operating Profit ($M)($M)
1,7971,9661,8081,7831,5621,7161,5951,4611,3401,4551,4081,367
Corporate Expenses, Net — GAAP ($M)($M)
-191-308-223-207-193-294-155-244-103-280-203-164
Corporate Expenses, Net — Non-GAAP Adjusted ($M)($M)
-144-209-156-151-138-157-132-170-35-193-147-159
Corporate — Depreciation & Amortization ($M)($M)
455144413735343435
Corporate — Expenditures for Long-Lived Assets ($M)($M)
4340456377129658459
U.S. Pharmaceutical (Legacy Segment Pre-Q2 FY26 Reorg) — Revenue ($M)($M)3
89,95483,16687,11085,72671,71568,79073,02369,766
International (Legacy Segment Pre-Q2 FY26 Reorg) — Revenue ($M)($M)3
3,7383,4613,8603,7093,6913,5483,6393,475
McKesson Ventures Equity Investments Pre-Tax Net Gains/(Losses) ($M)($M)
-1511316-15110-8-10
Non-GAAP Adjusted Earnings ($M)($M)7
1,1831,4341,1551,2271,0371,2741,0169151,0298131,032841
Non-GAAP Adjusted Diluted EPS ($/Share)($)
9.9311.699.349.868.2610.128.037.077.886.187.746.23
Non-GAAP Adjusted Gross Profit ($M)($M)
3,6773,8623,6623,5343,2643,3883,3423,2463,0603,3153,1313,045
Non-GAAP Adjusted Operating Expenses ($M)($M)
-2,090-2,141-2,084-1,964-1,904-1,885-1,948-1,989-1,927-2,087-1,904-1,863
Consolidated Non-GAAP Adjusted Operating Profit (Adjusted EBIT, $M)($M)
1,6531,7571,6521,6321,4241,5591,4631,2911,3051,2621,2611,208
Consolidated GAAP Operating Profit (Income from Continuing Operations Before Interest & Taxes, $M)($M)
1,3852,1861,6931,4691,1001,5601,2936121,1591,250676977
Non-GAAP Adjusted Interest Expense ($M)($M)
-75-59-59-68-44-40-62-72-70-75-58-55
Non-GAAP Adjusted Income Tax Expense ($M)($M)
-340-206-366-273-295-197-335-256-160-334-127-271
Total Pre-Tax Non-GAAP Adjustments to Operating Profit ($M)($M)6
268-429-41163324-117067914612585231
Amortization of Acquisition-Related Intangibles (Pre-Tax Adjustment, $M)($M)
747373805050536063636262
Transaction-Related Expenses & Adjustments (Pre-Tax Adjustment, $M)($M)
224655565566
LIFO Inventory-Related Credits/(Charges) (Pre-Tax Adjustment, $M)($M)
-2-182-10-11-7-389-2-2-246255
Gains from Antitrust Legal Settlements (Pre-Tax Adjustment, $M)($M)
-60-150-8-260-31-63-90-24-23-79
Restructuring, Impairment & Related Charges, Net (Pre-Tax Adjustment, $M)($M)
1369936634773321711031428
Claims & Litigation Charges, Net (Opioid & Related Settlements, Pre-Tax Adjustment, $M)($M)
-34-10-2000-41121490-2
Non-GAAP Free Cash Flow ($M)($M)2
-3723,2361,0572,224-1,1077,470-2,5791,882-1,5473,878100825
Payments for Property, Plant & Equipment (Schedule 6 FCF Reconciliation, $M)($M)
1121111081061111691261361061889075
Capitalized Software Expenditures ($M)($M)
4074679078109708261816465
Full-Year Guidance: Adjusted Diluted EPS — Low End ($/Share)($)3
44.2043.8038.8038.3537.1036.7532.5532.4031.7531.2527.2526.80
Full-Year Guidance: Adjusted Diluted EPS — High End ($/Share)($)
4544.6039.2038.8537.9037.5532.953332.5532.0527.6527.40
Full-Year Guidance: Non-GAAP Free Cash Flow — Low End ($M)($M)
4,5004,5004,4004,4004,4004,4004,8004,8004,8004,8003,700
Full-Year Guidance: Non-GAAP Free Cash Flow — High End ($M)($M)
4,9004,9004,8004,8004,8004,8005,2005,2005,2005,2004,100
Total Opioid-Related Settlement Liabilities on Balance Sheet ($M)($M)3
5,6605,6925,7085,7206,3776,3776,3926,3926,8926,7786,6446,644
Current Opioid Litigation Liabilities (Within Accrued Expenses, $M)($M)
602601605617776776775775778665516516
Long-Term Opioid Litigation Liabilities ($M)($M)
5,0585,0915,1035,1035,6015,6015,6175,6176,1146,1136,1286,128
Total Noncurrent Litigation Reserve (XBRL LossContingencyAccrualCarryingValueNoncurrent, $M)($M)
5,0585,0915,1035,1035,6015,6015,6175,6176,1146,1136,1286,128
LIFO Inventory Valuation Reserve ($M)2
Restructuring Liability Reserve Balance ($M)($M)
744435708812615718843555466
Restructuring, Impairment & Related Charges (GAAP Note 4, $M)($M)
1363663473223410428
Consolidated Long-Lived Assets, Net (Geographic Footnote Total, $M)($M)2
3,4293,4323,3803,3573,2823,1832,811
United States Long-Lived Assets, Net ($M)($M)
3,1853,1773,1263,0962,9522,8772,477
Foreign / International Long-Lived Assets, Net ($M)($M)
244255254261330306334
Operating Lease Right-of-Use (ROU) Assets ($M)($M)2
1,9412,0582,0561,9912,1681,7821,7581,4951,7351,7291,6791,680
Operating Lease Liabilities — Current ($M)($M)
292287286278297258256243296295296296
Operating Lease Liabilities — Noncurrent ($M)($M)
1,6801,8011,7811,7561,8591,4781,4891,2321,4661,4661,4211,436
Remaining Share Repurchase Authorization ($M)($M)2
5,1752,7195,3816,0706,8797,4697,7398,5606,0886,6157,3008,100
Total Shares Repurchased in Quarter (Open Market + ASR + Tax Withholding, Millions)(M)
3.602.500.801.200.800.501.502.9011.301.902
Common Stock Repurchased Value (XBRL StockRepurchasedDuringPeriodValue, $M)($M)
2,5696968175928211,529528868840
U.S. Federal Government Prime Contract Obligations to McKesson ($M)($M)
3,8793,4043,8513,4993,1982,5152,7272,2642,1362,1351,7372,157
Peer Benchmark: Cencora, Inc. (COR) — Consolidated Revenue ($M)($M)3
84,75578,35685,93280,66475,45481,48774,24168,41472,253
Cencora (COR) — GAAP Operating Income ($M)($M)
1,1201,1437608681,036706673553823
Cencora (COR) — GAAP Net Income ($M)($M)
7641,641560687718489484421602
Cencora (COR) — Merchandise Inventories ($M)($M)
21,03020,01024,07920,49320,13818,96620,50818,99918,30217,63118,65217,455
Peer Benchmark: Cardinal Health, Inc. (CAH) — Consolidated Revenue ($M)($M)3
65,62764,00954,87855,26452,27754,86857,44254,650
Cardinal Health (CAH) — GAAP Operating Income/(Loss) ($M)($M)
707668730549568369505-32
Cardinal Health (CAH) — GAAP Net Income/(Loss) ($M)($M)
467450506400416261368-12
Cardinal Health (CAH) — Merchandise Inventories ($M)($M)
17,29720,11617,55916,83116,15816,90415,61914,95717,27718,45116,987
Peer Benchmark: Option Care Health, Inc. (OPCH) — Consolidated Revenue ($M)($M)3
1,4421,3511,4351,4161,3331,2791,2271,1461,093
Consolidated Revenue (GAAP, $M)($M)18
105,38096,295106,158103,15097,82790,82395,29493,65179,28376,35580,89877,215
Cost of Sales (GAAP, $M)($M)
101,69592,251102,47399,60894,54887,18492,01090,40376,13172,77077,74674,146
Gross Profit (GAAP, $M)($M)
3,6854,0443,6853,5423,2793,6393,2843,2483,1523,5853,1523,069
Total Operating Expenses (GAAP, $M)($M)
2,3661,8942,0662,1352,2432,0482,0602,6702,1232,3692,5102,118
Selling, Distribution & Administrative Expenses (GAAP, $M)($M)
2,2641,7962,0302,0742,1961,9752,0282,5032,0012,1892,5062,092
Restructuring, Impairment & Related Charges (GAAP Income Statement, $M)($M)
1369936634768322341031428
Claims & Litigation Settlement Charges (GAAP, $M)($M)
341020004-112-14902
Operating Income (GAAP, $M)($M)
1,3192,1501,6191,4071,0361,5911,2245781,0291,216642951
Interest Expense (GAAP, $M)($M)
776163744945677875806461
Income from Continuing Operations Before Income Taxes (GAAP, $M)($M)
1,3082,1251,6301,3951,0511,5151,2265341,0841,170612916
Income Tax Expense/(Benefit) (GAAP, $M)($M)
276270380232220209298247124340-18213
Net Income/(Loss) Including Noncontrolling Interests (GAAP, $M)($M)
1,0321,8551,2501,1638311,306928287960830630703
Net Income Attributable to Noncontrolling Interests (GAAP, $M)($M)
41817364534746494645394139
Net Income/(Loss) Attributable to McKesson Corporation (GAAP, $M)($M)
6141,6821,1861,1107841,260879241915791589664
Diluted Earnings/(Loss) Per Common Share (GAAP, $/Share)($)
5.159.598.926.256.951.8774.424.92
Basic Earnings/(Loss) Per Common Share (GAAP, $/Share)($)
5.179.638.956.286.981.887.044.454.95
Dividends Declared Per Common Share ($/Share)($)
0.820.820.820.820.710.710.710.710.620.620.620.62
Diluted Weighted-Average Common Shares (Millions)(M)
119124124126127129131133135
Basic Weighted-Average Common Shares (Millions)(M)
119123124125126129130133134
Total Assets (GAAP, $M)($M)18
88,33082,32384,19084,16081,31175,14071,08172,42971,67067,44366,51266,091
Cash & Cash Equivalents ($M)($M)
5,1643,9752,9594,0042,4185,9561,1312,5092,3024,5831,9822,524
Receivables, Net ($M)($M)
30,31627,98528,21328,28628,15825,64325,83125,27023,74321,62223,06622,494
Inventories, Net ($M)($M)
26,25924,20727,06726,13425,06523,00123,83724,17625,57121,13922,02021,945
Prepaid Expenses & Other Current Assets ($M)($M)
1,0981,0431,4581,4631,1601,063942751636626572568
Total Current Assets ($M)($M)
62,83757,21059,69759,88756,80155,39851,74153,34152,25247,97047,64047,531
Property, Plant & Equipment, Net ($M)($M)
2,6842,6682,6342,6272,5742,5022,3972,3612,3572,3162,2012,171
Goodwill ($M)($M)
11,27811,31611,32411,28311,36510,02210,00410,08710,11810,1329,9739,934
Intangible Assets, Net ($M)($M)
4,0134,0794,1794,2204,2721,4641,5091,5732,0452,1102,0972,142
Other Noncurrent Assets ($M)($M)
5,5774,9924,3004,1524,1313,9723,6723,5723,1633,1862,9222,633
Drafts & Accounts Payable ($M)($M)
63,73159,97360,68360,93857,86155,33049,68953,31751,70447,09746,69946,795
Accrued Expenses & Other Current Liabilities ($M)($M)
5,0365,4906,0305,0684,9244,8255,0274,7874,3834,9154,4004,007
Total Current Liabilities ($M)($M)
70,35667,01768,13168,03164,33161,60458,56258,77156,43452,35751,66151,147
Long-Term Debt ($M)($M)
8,4325,2595,4256,0116,5284,4634,4225,6915,5845,5795,6255,535
Long-Term Litigation & Other Noncurrent Liabilities ($M)($M)
2,7422,6592,7412,7512,8682,6592,6032,7122,5252,6102,3812,197
Retained Earnings ($M)($M)
22,80822,29120,71019,62218,61617,92116,75215,95915,81014,97814,26813,761
Treasury Shares, at Cost ($M)($M)
-34,890-32,005-29,654-28,955-28,137-27,439-27,141-26,310-24,781-24,119-23,474-22,604
McKesson Corporation Stockholders' Deficit/Equity ($M)($M)
-4,240-2,172-1,298-1,739-1,967-2,074-3,084-3,017-1,755-1,971-2,053-1,828
Total Deficit/Equity Including Noncontrolling Interests ($M)($M)
-3,864-1,777-901-1,355-1,588-1,694-2,704-2,642-1,381-1,599-1,682-1,464
Operating Cash Flow (GAAP, $M)($M)13
-2203,4211,2322,420-9187,748-2,3832,100-1,3804,147254965
Depreciation & Amortization (Cash Flow Statement, $M)($M)
195-246188188157-213153163169
Changes in Receivables ($M)($M)
-2,374131166-207-2,089129-565-1,398-2,1011,344-1,091-827
Changes in Inventories ($M)($M)
-2,0743,016-899-1,228-1,9718641761,132-4,4421,090-35-1,523
Changes in Drafts & Accounts Payable ($M)($M)
3,773-574-2793,2231,9475,624-3,5441,6054,616424-1442,834
Additions to Property, Plant & Equipment (GAAP CapEx, $M)($M)
1121111081061111691261361061889075
Acquisitions, Net of Cash & Cash Equivalents Acquired ($M)($M)
-23-4-23-30-3,359-21-2-10-266-60
Net Cash Used in Investing Activities (GAAP, $M)($M)
-214425-269-24-3,564-224-136-286-87-577-180-166
Proceeds from Issuances of Long-Term Debt ($M)($M)
3,2150001,990004980000
Repayments of Long-Term Debt ($M)($M)
-1-8-1,197-20-9-9-5010-8-9-3
Common Stock Repurchases (Cash Outflow, $M)($M)
2,5302,6716808185813008271,492527678842809
Dividends Paid ($M)($M)
102101101899091928082828375
Net Cash Used in Financing Activities (GAAP, $M)($M)
1,632-2,820-2,026-9611,176-2,8551,298-1,599-809-968-622-909
Net Change in Cash, Cash Equivalents & Restricted Cash ($M)($M)
1,1881,015-1,0561,426-3,2734,674-1,229207-2,2812,602-541-113

31 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Core operational KPIs — GLP-1 Medications Distribution Revenue ($15,000M in Q1 FY27, +23% YoY; $53,000M in FY26, +27% YoY; $41,000M in FY25 across 10 consecutive quarters FY2024Q4–FY2027Q1), U.S. Pharmaceutical Primary Distribution Centers (28) & Strategic Redistribution Centers (2), Health Mart Independent Franchise Pharmacies (3,900 in the U.S.) & McKesson Canada Banner Pharmacies (1,700), and Prescription Technology Solutions (RxTS) Prevented Abandoned Prescriptions (12.0 million in FY26) — are extracted from McKesson Form 10-K Item 1 and Quarterly Earnings Call Transcripts.
  • Complete realigned 4-segment operating performance (North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, Medical-Surgical Solutions, and Other/Corporate) across 9 quarters (FY2025Q1–FY2027Q1) and 3 fiscal years (FY2024–FY2026), including GAAP Operating Profit, Non-GAAP Adjusted Operating Profit, GAAP & Non-GAAP Operating Profit Margins, ASU 2023-07 Significant Segment Operating Expenses (`Other segment expense, net`), Segment Depreciation & Amortization, and Segment Capital Expenditures, plus 25–30 quarters of pre-reorganization history for U.S. Pharmaceutical and International.
  • Consolidated Non-GAAP reconciliation series (Adjusted Earnings, Adjusted Diluted EPS, Adjusted Gross Profit, Adjusted Operating Expenses, Adjusted EBIT, Pre-Tax Adjustments Breakdown for Intangible Amortization, Transaction Expenses, LIFO Credits/Charges, Antitrust Settlement Gains, Restructuring, and Opioid/Litigation Claims) and Schedule 6 Non-GAAP Free Cash Flow & Capitalized Software Expenditures are compiled across 26–29 quarters through Q1 FY27, alongside Full-Year Guidance Evolution and the 2025 Investor Day 6-Year Non-GAAP Track Record.
  • Only directly reported point figures and cumulative year-to-date period splits (`quarter = year-to-date − previous year-to-date` and `Q4 = full year − nine months` on cash flow and segment expense tables) are included; no self-computed ratios, margins, or growth rates are added. Consolidated-minus-standalone parent subtraction is not applicable because McKesson Corporation files consolidated US GAAP financial statements on Form 10-K without standalone parent-company operating revenue.
  • Metrics that switched from exact point disclosures to approximate bounds in recent periods (The US Oncology Network provider count >3,300 / >3,400 in Q2/Q4 FY26 & Q1 FY27; worldwide total headcount >43,000 in FY26; RxTS annual patient savings 'over $9B / over $10B' in FY22–FY25) are excluded from active series and documented in `excluded`.

Không hiện vì thiếu các kỳ gần đây (15)

  • Core Operational KPIs › U.S. Strategic Redistribution Centers Total Square Footage — Disclosed only as bound 'over 2.4 million square feet' across FY2020–FY2026 Form 10-K filings
  • Core Operational KPIs › RxTS Connected Pharmacies & Providers Network — Disclosed only as bounds ('50,000+ pharmacies', '950,000+ providers') in 2025 Investor Day Presentation
  • Oncology & Multispecialty › Sarah Cannon Research Institute (SCRI) Clinical Trials & Accruals — Disclosed only as cumulative bounds ('850+ first-in-human trials', '300+ FDA approvals', 'over 1,000 clinical trials') in 2025 Investor Day & 10-K
  • Core Operational KPIs: GLP-1 Distribution, Pharmacy & DC Network & RxTS Scale › The US Oncology Network Providers (Disclosed Exact Points Only; Switched to >3,300 / >3,400 Bounds in Q2/Q4 FY26 & Q1 FY27)
  • Core Operational KPIs: GLP-1 Distribution, Pharmacy & DC Network & RxTS Scale › The US Oncology Network Sites of Care (Disclosed Exact Points Only; Switched to >700 Bound in Q2 FY26)
  • Core Operational KPIs: GLP-1 Distribution, Pharmacy & DC Network & RxTS Scale › The US Oncology Network States Covered (Not Disclosed in Q2 FY26–Q1 FY27)
  • Core Operational KPIs: GLP-1 Distribution, Pharmacy & DC Network & RxTS Scale › RxTS Annual Patient Medication Savings (Only FY2026 Disclosed as Exact $10B; FY2022–FY2025 Disclosed as Bounds 'over $9B / over $10B')
  • Consolidated Non-GAAP Profitability, Free Cash Flow & Full-Year Guidance Evolution › Non-GAAP Adjusted Earnings ($M) › Non-GAAP Adjusted Other Income, Net ($M)
  • Consolidated Non-GAAP Profitability, Free Cash Flow & Full-Year Guidance Evolution › Full-Year Guidance: Adjusted Diluted EPS — Low End ($/Share) › Full-Year Guidance: Adjusted Corporate Expenses — Low End ($M)
  • Consolidated Non-GAAP Profitability, Free Cash Flow & Full-Year Guidance Evolution › Full-Year Guidance: Adjusted Diluted EPS — Low End ($/Share) › Full-Year Guidance: Adjusted Corporate Expenses — High End ($M)
  • Consolidated Non-GAAP Profitability, Free Cash Flow & Full-Year Guidance Evolution › Full-Year Guidance: Adjusted Diluted EPS — Low End ($/Share) › Full-Year Guidance: Adjusted Interest Expense — Low End ($M)
  • Consolidated Non-GAAP Profitability, Free Cash Flow & Full-Year Guidance Evolution › Full-Year Guidance: Adjusted Diluted EPS — Low End ($/Share) › Full-Year Guidance: Adjusted Interest Expense — High End ($M)
  • Customer & Supplier Concentration, Workforce, Opioid Liabilities, LIFO, Leases & Share Repurchases › Total Employees Worldwide (Disclosed as Bound 'more than 43,000' in FY2026; Exact 45,000–80,000 in FY2020–FY2025)
  • Customer & Supplier Concentration, Workforce, Opioid Liabilities, LIFO, Leases & Share Repurchases › LIFO Inventory Valuation Reserve ($M) › Effect of LIFO Inventory Liquidation / Period Charge ($M)
  • Consolidated GAAP Financial Statements & XBRL Segment Baseline › Segment Baseline (XBRL): North American Pharmaceutical Revenue ($M) › Segment Baseline (XBRL): Other / International Revenue ($M)

Dữ liệu cập nhật 2026-11-03.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của McKesson

See a number that looks wrong?